Charles River posts Q4 loss on preclinical writedown

A steep write-down related to its preclinical services business pushed Charles River Laboratories to a fourth-quarter loss, but adjusted results still exceeded Wall Street's expectations. Report

Suggested Articles

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.